. 2023 Feb 16;9:17. doi: 10.1038/s41526-023-00260-9

Table 5.

Management—Gap Analysis and Recommendations.

Gap	Recommendation
We do not know potency or efficacy of traditional anticoagulant therapies in the microgravity environment.	The risks of anticoagulation in space and optimal reversal strategies for anticoagulants during space flight must be determined, specifically the role of DOACs and their reversal agents. Characterize the anticoagulant drug levels and pharmacokinetics we can expect in space travellers and the haemodynamic effects of anticoagulants in microgravity.
We do not know if follow-up from a VT event should be conducted in space or on the ground post mission.	Access existing longitudinal health data from astronauts to assess long term cardiovascular health including sequelae of VT to determine if existing long term follow up is suitable.

Gap

Recommendation

We do not know potency or efficacy of traditional anticoagulant therapies in the microgravity environment.

The risks of anticoagulation in space and optimal reversal strategies for anticoagulants during space flight must be determined, specifically the role of DOACs and their reversal agents.

Characterize the anticoagulant drug levels and pharmacokinetics we can expect in space travellers and the haemodynamic effects of anticoagulants in microgravity.

We do not know if follow-up from a VT event should be conducted in space or on the ground post mission.

Access existing longitudinal health data from astronauts to assess long term cardiovascular health including sequelae of VT to determine if existing long term follow up is suitable.